Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pema-heart: Effect of Pemafibrate on Left Ventricular Diastolic Function in Patients with Type 2 Diabetes
jRCTs061260010Recruiting
- Sponsor
- Kowa Company, Ltd.
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of pemafibrate in type 2 diabetes mellitus (T2DM), hypertriglyceridemia and left ventricular diastolic dysfunction (LVDD) (2 arms), sponsored by Kowa Company, Ltd. Started Jun 2026; status: recruiting.
02
Drugs
pemafibrate
03
Conditions
type 2 diabetes mellitus (T2DM)hypertriglyceridemialeft ventricular diastolic dysfunction (LVDD)
Beyond the preview
Go deeper on jRCTs061260010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061260010.